✨ Free AI Report
Arvinas, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Arvinas, Inc.
Research Preview

Arvinas, Inc.: Business Overview, Financials & Competitive Analysis

Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapies through its PROTAC platform, designed to degrade disease-causing proteins using the body's natural protein disposal s...

Analyst-debate audio for Arvinas, Inc.

AskCyborg analysts argue the bull and bear cases for Arvinas, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Arvinas, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
6/ 10Solid

Cyborg Score thesis

Clinical-stage biotech with innovative PROTAC platform approaching regulatory catalysts, but elevated execution risk and cash...

Read the full analyst-debate transcript →
Industry Biotechnology - Targeted Protein Degradation
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Arvinas, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Arvinas, Inc. Overview

Pro stress-test →

Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapies through its PROTAC platform, designed to degrade disease-causing proteins using the body's natural protein disposal system. The company is advancing a robust pipeline with multiple clinical programs targeting oncology, neurodegenerative diseases, and other serious conditions.

Strategic Profile

Pro stress-test →

Arvinas is progressing multiple investigational drugs through clinical development including ARV-102 for neurodegenerative disorders, ARV-806 for KRAS G12D mutations, ARV-393 for non-Hodgkin Lymphoma, and vepdegestrant for ER+/HER2- breast cancer. The company has collaborations with Pfizer, Genentech, Roche, Carrick Therapeutics, and Bayer.

Competitive Landscape

Pro stress-test →

Arvinas operates in the targeted protein degradation space with differentiation through its PROTAC platform technology. Competitors include Relay Therapeutics ($1.36B market cap) and Nurix Therapeutics ($1.77B market cap), both also in biotechnology. Arvinas' focus on multiple oncology and neurology programs with major pharma partnerships differentiates it within the segment.

Industry Context

Arvinas, Inc. operates in Biotechnology - Targeted Protein Degradation.

Key facts

Founded: 2013 · Headquarters: New Haven, Connecticut · Revenue: $312.3M · Market cap: $820M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Arvinas, Inc..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Arvinas, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

RLAYClinical-stage biotech focusing on protein degradation→NRIXOncology-focused targeted protein degradation biotech→

Compare Arvinas, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Arvinas, Inc. operates in Biotechnology - Targeted Protein Degradation. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Targeted Protein Degradation research →
NEW · MCP server

Ask your AI assistant about Arvinas, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Arvinas, Inc. and its top competitor on Cyborg Score”
“What did Arvinas, Inc. do this quarter?”
“Is Arvinas, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Arvinas, Inc. do?+
Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapies through its PROTAC platform, designed to degrade disease-causing proteins using the body's natural protein disposal s...
What is Arvinas, Inc.'s Cyborg Score?+
Arvinas, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Arvinas, Inc.'s main competitors?+
Named competitors include RLAY, NRIX. The full competitive landscape is in the AskCyborg report.
How can I get the full Arvinas, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Arvinas, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Arvinas, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.